Atom Investors LP purchased a new stake in Guardant Health Inc (NASDAQ:GH) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 46,670 shares of the company’s stock, valued at approximately $3,786,000.
Several other institutional investors have also recently modified their holdings of GH. CSat Investment Advisory L.P. acquired a new position in shares of Guardant Health during the 2nd quarter worth about $25,000. FinTrust Capital Advisors LLC raised its stake in Guardant Health by 1,930.0% in the first quarter. FinTrust Capital Advisors LLC now owns 406 shares of the company’s stock valued at $28,000 after buying an additional 386 shares during the period. First Horizon Advisors Inc. raised its stake in Guardant Health by 186.0% in the first quarter. First Horizon Advisors Inc. now owns 429 shares of the company’s stock valued at $28,000 after buying an additional 279 shares during the period. Fifth Third Bancorp acquired a new stake in shares of Guardant Health in the second quarter valued at approximately $52,000. Finally, Watson Rebecca bought a new position in shares of Guardant Health during the 2nd quarter worth approximately $57,000. Institutional investors own 84.23% of the company’s stock.
In related news, Director Stanley J. Meresman sold 6,000 shares of the stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $80.59, for a total transaction of $483,540.00. Following the transaction, the director now directly owns 7,302 shares of the company’s stock, valued at $588,468.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Derek A. Bertocci sold 9,992 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $94.39, for a total transaction of $943,144.88. Following the transaction, the chief financial officer now directly owns 44,159 shares in the company, valued at $4,168,168.01. The disclosure for this sale can be found here. Insiders sold a total of 1,385,130 shares of company stock worth $116,545,437 over the last three months. 13.00% of the stock is owned by company insiders.
Several equities research analysts have issued reports on the company. Zacks Investment Research downgraded Guardant Health from a “buy” rating to a “hold” rating in a report on Wednesday, August 12th. BTIG Research started coverage on Guardant Health in a report on Thursday, June 11th. They set a “buy” rating and a $100.00 target price on the stock. Finally, BidaskClub cut Guardant Health from a “buy” rating to a “hold” rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $110.17.
Shares of Guardant Health stock traded down $1.86 during trading on Friday, reaching $90.81. 655,866 shares of the company’s stock were exchanged, compared to its average volume of 850,231. The firm’s 50-day moving average price is $87.42 and its 200 day moving average price is $81.30. Guardant Health Inc has a 1-year low of $55.90 and a 1-year high of $100.00. The company has a market cap of $9.03 billion, a P/E ratio of -71.50 and a beta of 0.60.
Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.17). Guardant Health had a negative return on equity of 13.35% and a negative net margin of 45.53%. The firm had revenue of $66.30 million for the quarter, compared to the consensus estimate of $59.18 million. During the same period in the prior year, the business earned ($0.13) EPS. Guardant Health’s quarterly revenue was up 22.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Guardant Health Inc will post -1.48 EPS for the current fiscal year.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Story: How is inflation measured?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.